GlassScriptPhysician profile
Kyle J Mccarthy
NPI 1346693504
$3,194.10
in general payments reported to CMS, 2019-2025
29 companies · $963 in 2025
The $963 reported for 2025 was more than what 86% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.89 · 2022: $702 · 2023: $770 · 2024: $736 · 2025: $963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,468.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $799.85 | 2022-2025 | |
| Novo Nordisk INC | $432.47 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $279.13 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Otsuka America Pharmaceutical, INC. | $227.81 | 2023-2025 | Rexulti, Abilify Maintena |
| Lilly USA, LLC | $202.09 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $171.23 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.38 | 2022-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $130.28 | 2022-2024 | |
| Pfizer INC. | $117.65 | 2023-2025 | |
| Axsome Therapeutics, INC. | $79.95 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $65.95 | 2022-2025 | |
| Almatica Pharma LLC | $59.08 | 2022-2024 | Loreev Xr, Gralise |
| Glaxosmithkline, LLC. | $58.17 | 2022-2025 | Trelegy Ellipta, Bexsero |
| Aimmune Therapeutics, INC. | $53.50 | 2024-2025 | Zenpep |
| Amgen INC. | $45.97 | 2022-2024 | Repatha, Otezla |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $40.32 | 2025 | Jornay Pm |
| Verona Pharma, INC. | $39.77 | 2025 | Ohtuvayre |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.90 | 2023 | Xifaxan, Trulance |
| Esperion Therapeutics, INC. | $34.01 | 2024-2025 | Nexletol |
| Scpharmaceuticals INC. | $26.97 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $21.68 | 2025 | Cobenfy |
| Myriad Genetic Laboratories, INC. | $19.54 | 2022 | |
| Dexcom, INC. | $19.11 | 2022 | |
| Viatris Specialty LLC | $17.20 | 2025 | Yupelri |
| Phathom Pharmaceuticals, INC. | $17.00 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $15.68 | 2024 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $15.67 | 2024 | Trintellix |
| Astellas Pharma US INC | $15.58 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $14.16 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Mccarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.